CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
Company Information
About this company
Key people
Kevin Hykes
President, Chief Executive Officer, Director
Jared Oasheim
Chief Financial Officer
Brent Binkowski
Chief Operating Officer
Paul Verrastro
Chief Marketing and Strategy Officer
Philip B. Adamson
Chief Medical Officer
Robert John
Chief Revenue Officer
Joseph P. Slattery
Lead Independent Director
Kevin Ballinger
Independent Director
Mitchell C. Hill
Independent Director
Mudit K. Jain
Independent Director
Kirk Nielsen
Independent Director
Click to see more
Key facts
- Shares in issue26.21m
- EPICCVRX
- ISINUS1266381052
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$176.13m
- Employees206
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.